Duke Eye Center pioneers cell-based gene therapy for rare retinal disease
A team at Duke Eye Center has become the first in a U.S. academic medical center to implant a new cell-based gene therapy for macular telangiectasia type 2 (MacTel), a rare retinal disorder that leads to progressive central vision loss.
























